Marinus Pharmaceuticals(US:MRNS) Prnewswireยท2024-06-28 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Marinus Pharmaceuticals, Inc. regarding allegations of misleading statements and failure to disclose critical information related to clinical trials [1][2]. Allegations - The complaint alleges that Marinus Pharmaceuticals understated the risk of failing to meet early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE) [2]. - It is claimed that the company did not disclose that failing to meet these criteria could lead to the cessation of the separate Phase 3 RAISE II trial [2]. - As a result, the statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [2]. Shareholder Information - Shareholders who purchased MRNS shares during the specified class period (March 17, 2021, to May 7, 2024) are encouraged to register for participation in the class action [6]. - The deadline for shareholders to seek lead plaintiff status is August 5, 2024 [6]. - There is no cost or obligation for shareholders to participate in the case [3][5]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].